FDA 483 - Instituto Grifols, S.A. - November 17, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Instituto Grifols, S.A. identified significant deficiencies in their quality control and complaint handling systems. The firm failed to adequately investigate customer complaints for Fibrin Sealant and did not thoroughly review unexplained discrepancies for Flebogamma, including issues with raw data traceability. Additionally, the inspection revealed unjustified deviations from production procedures, inadequate written procedures for production controls, and a failure to follow their stability testing program, particularly concerning out-of-specification results.
ID · 98a4876f-4fd1-47c1-9c57-bae31b325cd6